Texas Yale Capital Corp. Has $4.51 Million Stake in Eli Lilly and Company (NYSE:LLY)

Key Points

• Texas Yale Capital Corp. decreased its holdings in Eli Lilly and Company by 20.7%, selling 1,430 shares, and now owns 5,462 shares valued at approximately $4.51 million.
• Multiple institutional investors have adjusted their positions in Eli Lilly, with holdings by large investors making up 82.53% of the company's stock.
• Eli Lilly's recent quarterly earnings included $3.34 EPS, missing the consensus estimate, while the company announced a dividend of $1.50 to be paid on September 10th.

Texas Yale Capital Corp. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 20.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,462 shares of the company's stock after selling 1,430 shares during the period. Texas Yale Capital Corp.'s holdings in Eli Lilly and Company were worth $4,511,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Knightsbridge Asset Management LLC lifted its holdings in shares of Eli Lilly and Company by 1.9% in the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the last quarter. LS Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the last quarter. Prism Advisors Inc. acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $207,000. CSM Advisors LLC boosted its stake in Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after purchasing an additional 245 shares during the period. Finally, Bfsg LLC boosted its stake in Eli Lilly and Company by 1.4% during the 1st quarter. Bfsg LLC now owns 2,959 shares of the company's stock valued at $2,444,000 after purchasing an additional 42 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.6%

LLY stock traded down $4.91 during midday trading on Monday, reaching $807.78. The company had a trading volume of 2,586,280 shares, compared to its average volume of 2,753,392. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $765.57 billion, a P/E ratio of 59.06, a PEG ratio of 1.18 and a beta of 0.40. The company has a 50 day moving average of $771.95 and a two-hundred day moving average of $800.61.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the company earned $2.58 EPS. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.74%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LLY. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Finally, UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.